Medifast
MED
Market cap $143M

12.98 USD

-0.18

1.37%

At close Jun 13, 4:00 PM EDT

After hours

12.98

+0.00

0.00%

1 day

-1.37%

5 days

1.09%

1 month

2.04%

3 months

-6.42%

6 months

-32.25%

Year to date

-24.93%

1 year

-35.55%

5 years

-88.52%

10 years

-60.00%

About: Medifast Inc is a old health and wellness company known for its habit-based and coach-guided lifestyle solution OPTAVIA, which provides people with a simple, yet comprehensive approach to address obesity and support a healthy life. OPTAVIA provides unparalleled coaching support along with community, tailored nutrition and healthy habits, and empowers people to master their weight loss journey through each stage of life. The company has access to GLP-1 medications where clinically appropriate. Medifast remains committed to its mission of offering Lifelong Transformation, Making a Healthy Lifestyle Second Nature.

Employees: 504

Consumer Discretionary Personal Services

0

Funds holding %

of 7,296 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

129% more call options, than puts

Call options by funds: $7.34M | Put options by funds: $3.2M

10% less repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 41

4% less funds holding

Funds holding: 129 [Q4 2024] → 124 (-5) [Q1 2025]

6.21% less ownership

Funds ownership: 81.56% [Q4 2024] → 75.35% (-6.21%) [Q1 2025]

13% less first-time investments, than exits

New positions opened: 21 | Existing positions closed: 24

29% less capital invested

Capital invested by funds: $157M [Q4 2024] → $111M (-$46.1M) [Q1 2025]

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for MED.

See Analyst Rankings

Financial journalist opinion

Zacks Investment Research

Medifast (MED) Up 10.9% Since Last Earnings Report: Can It Continue?

Medifast (MED) reported earnings 30 days ago. What's next for the stock?

Medifast (MED) Up 10.9% Since Last Earnings Report: Can It Continue?

Zacks Investment Research

Medifast Q1 Loss Wider Than Expected, Sales Down 33.8% Y/Y

MED's first-quarter results show challenges from fewer active OPTAVIA Coaches. Nonetheless, the company is focusing on revitalizing its coach base for growth.

Medifast Q1 Loss Wider Than Expected, Sales Down 33.8% Y/Y

Medifast, Inc. (MED) Q1 2025 Earnings Call Transcript

Medifast, Inc. (NYSE:MED ) Q1 2025 Earnings Conference Call April 28, 2025 4:30 PM ET Company Participants Steven Zenker - Vice President, Investor Relations Dan Chard - Chairman and CEO Jim Maloney - Chief Financial Officer Nick Johnson - Chief Field Operations Officer Conference Call Participants Jim Salera - Stephens Doug Lane - Water Tower Research Operator Greetings. And welcome to the Medifast First Quarter 2025 Earnings Conference Call.

Medifast, Inc. (MED) Q1 2025 Earnings Call Transcript

Medifast Announces First Quarter 2025 Financial Results

BALTIMORE--(BUSINESS WIRE)--Medifast (NYSE: MED), the health and wellness company known for its habit-based and coach-guided lifestyle solution, OPTAVIA®, today reported results for the first quarter ended March 31, 2025. First Quarter 2025 Revenue of $115.7 million, with revenue per active earning coach of $4,556 Independent active earning OPTAVIA coaches of 25,400 Net loss of $0.8 million, which includes an unrealized gain on investment in LifeMD (Nasdaq: LFMD) common stock of $0.4 million (n.

Medifast Announces First Quarter 2025 Financial Results

Zacks Investment Research

Medifast to Report Q1 Earnings: What Investors Should Expect

MED's first-quarter results may show challenges in customer acquisition amid market headwinds and shifting consumer trends.

Medifast to Report Q1 Earnings: What Investors Should Expect

Zacks Investment Research

Medifast Trades Near 52-Week Low: What's the Best Move Now?

MED faces steep revenue declines and coach losses but aims to rebound through innovation, marketing and new GLP-1-focused initiatives.

Medifast Trades Near 52-Week Low: What's the Best Move Now?

Medifast: GLP-1 Caused A Vicious MLM Flywheel Effect

Medifast, Inc.'s business is deteriorating as GLP-1 medication has lowered demand, causing a vicious flywheel effect as coaches are exiting the platform. The company is trying to reposition itself as a GLP-1 adjacent business, but the repositioning hasn't shown results so far with a deteriorating immediate earnings outlook. MED stock now trades below the company's net cash position, but due to high earnings uncertainty, the low valuation is justified.

Medifast: GLP-1 Caused A Vicious MLM Flywheel Effect

Zacks Investment Research

MED Q4 Earnings Beat, Revenues Dip Y/Y on Lower Customer Acquisition

Medifast's Q2 results show challenges related to weak customer acquisition. However, it is prioritizing efforts to enhance coach productivity in the near term.

MED Q4 Earnings Beat, Revenues Dip Y/Y on Lower Customer Acquisition

Medifast, Inc. (MED) Q4 2024 Earnings Call Transcript

Medifast, Inc. (NYSE:MED ) Q4 2024 Earnings Conference Call February 18, 2025 4:30 PM ET Company Participants Steven Zenker - Vice President, Investor Relations Dan Chard - Chairman and Chief Executive Officer Jim Maloney - Chief Financial Officer Conference Call Participants James Salera - Stephens Linda Bolton-Weiser - D.A. Davidson Operator Greetings and welcome to the Medifast Fourth Quarter 2024 Earnings Conference Call.

Medifast, Inc. (MED) Q4 2024 Earnings Call Transcript

Zacks Investment Research

Medifast (MED) Q4 Earnings and Revenues Beat Estimates

Medifast (MED) came out with quarterly earnings of $0.10 per share, beating the Zacks Consensus Estimate of a loss of $0.27 per share. This compares to earnings of $1.09 per share a year ago.

Medifast (MED) Q4 Earnings and Revenues Beat Estimates

See News Rankings

Charts implemented using Lightweight Charts™